Study of Oral PG-116800 Following a Heart Attack

PHASE2CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Myocardial InfarctionHeart FailureHeart Enlargement
Interventions
DRUG

PG-116800 (given as PG-530742)

200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days

DRUG

Placebo tablet

placebo tablet, twice a day for 90 days

Trial Locations (52)

14642

Strong Memorial Hospital, Rochester

27401

Moses Cone Hospital, Greensboro

28204

Presbyterian Hospital, Charlotte

29403

Medical University of South Carolina, Charleston

30309

Piedmont Hospital, Atlanta

33462

JFK Medical Center, Atlantis

33756

Morton Plant Hospital, Clearwater

48202

Henry Ford Hospital, Detroit

63110

Barnes Jewish Hospital, St Louis

72205

University of Arkansas for Medical Sciences and Central Arkansas Veterans Health Care System, Little Rock

73120

Oklahoma Heart Hospital, Oklahoma City

77030

Memorial Hermann Hospital, Houston

80210

Porter Adventist Hospital, Denver

95340

Mercy Community Medical Center, Merced

06030-2202

University of Connecticut Health Center, Farmington

55407-1139

Abbott-Northwestern Hospital, Minneapolis

15601-2745

Westmoreland Regional Hospital, Greensburg

17033-0850

Hershey Medical Center, Hershey

02903

Rhode Island Hospital, Providence

37404-1127

Memorial Hospital, Chattanooga

26506-9157

West Virginia University Hospital, Morgantown

T2N 4N1

Foothills Hospital, Calgary

T5G 3C8

Royal Alexandra Hospital, Edmonton

T6G 2B7

University of Alberta Hospital, Edmonton

T6L 5X8

Grey Nuns Hospital, Edmonton

V9W 5Y4

Alder Medical Centre, Campbell River

V5Z 4E3

Vancouver General Hospital, Vancouver

V8R 4R2

Victoria Heart Institute, Victoria

A1B 3V6

St. John's HSC, Saint John's

B3H 3H7

Queen Elizabeth II HSC, Halifax

L3Y 2R2

Southlake Regional HC, Newmarket

M1S 4V5

Scarborough Grace Hospital, Scarborough Village

M4C 3E7

Toronto East General, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

J1H 5N4

CHUS, Hopital Fleurimont, Fleurimont

H1T 1C8

Montreal Heart Institute, Montreal

H3A 1A1

McGill University Health Centre, Royal Victoria Hospital, Montreal

H3G 1A4

Montreal General Hospital, Montreal

H4J 1C5

Hopital Sacre-Coeur, Montreal

G1V 4G5

Hopital Laval, Ste-Foy

Unknown

Klinika Kardiologii, Panstwowy Szpital Kliniczny, Bialystok

Katedra i Klinika Kardiologii i Chorob Wewnetznych, Akademia Medyczna w Bydgoszczy, Bydgoszcz

1 Katedra Kardiologii Slaskiej Akademii Medycznej, Katowice

Klinika Chorob Serca i Naczyn, Krakowski Szpital Specjalistyczny, Krakow

Oddzial Kardiologii, Wojewodzki Szpital Specjalistyczny, Krakow

I Klinika Kardilogii Akademii Medycznej w Poznaniu, Poznan

Oddzial Internistyczno-Kardiologiczny, Samodzieiny Publiczny Wojewodzki Szpital Zespolony, Szczecin

I Klinika Choroby Wiencowej, Instytut Kardiologii w Warszawie, Warsaw

Klinika Choroby Wiencowej, Instytut Kardiologi w Warszawie, Warsaw

Klinika Kardilogii Inwazyjnej, Centrainy Szpital MSWiA, Warsaw

Klinika Kardiologii, Szpital Grochowski, Warsaw

Klinika Kardiologii IMW, Uniwersytet Medyczny w Lodzi, Lodz

All Listed Sponsors
lead

Procter and Gamble

INDUSTRY

NCT00067236 - Study of Oral PG-116800 Following a Heart Attack | Biotech Hunter | Biotech Hunter